AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26385817 — intervention group
Group type: EXPERIMENTAL
Intervention: No formal education
Number of subjects: 9270
Study 26385817 — intervention group
Group type: COMPARATOR
Intervention: Education level
Number of subjects: 9270
Study 24512975 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Modification Program (AMP)
Number of subjects: 24
Study 24512975 — intervention group
Group type: COMPARATOR
Intervention: Attentional Control Program (ACC)
Number of subjects: 24
Study 21083771 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 40 puffs of 0.2 mg salbutamol
Number of subjects: 9
Study 21083771 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two placebo tablets)
Number of subjects: 9
Study 20532528 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified transanal endorectal pull-through (TEPT) procedure (Group B)
Number of subjects: 45
Study 20532528 — intervention group
Group type: COMPARATOR
Intervention: Conventional TEPT procedure (Group A)
Number of subjects: 45
Study 18797274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction and bladder retraining
Number of subjects: 0
Study 18797274 — intervention group
Group type: EXPERIMENTAL
Intervention: New anticholinergic medications
Number of subjects: 0
Study 18797274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical botulinum toxin
Number of subjects: 0
Study 15983464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Epidural Bolus (SEB) technique
Number of subjects: 16
Study 15983464 — intervention group
Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI) technique
Number of subjects: 16
Study 15983464 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in blocked segments between sides in SEB group
Number of subjects: 16
Study 15983464 — intervention group
Group type: COMPARATOR
Intervention: Difference in blocked segments between sides in CEI group
Number of subjects: 16
Study 12209503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 12209503 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg tacrolimus
Number of subjects: 268
Study 12209503 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg tacrolimus
Number of subjects: 268
Study 12209503 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tacrolimus
Number of subjects: 268
Study 10494483 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 100
Study 10494483 — intervention group
Group type: COMPARATOR
Intervention: IUD
Number of subjects: 100
Study 7476742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg oral tablet on admission, followed by 50 mg infusion in 250 ml dextrose 5% over 30 minutes)
Number of subjects: 20
Study 7476742 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg oral tablet and 100 mg infusion in 250 ml dextrose 5% over 30 minutes)
Number of subjects: 20
Study 1683545 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of activated charcoal administered simultaneously with 400 mg amiodarone
Number of subjects: 18
Study 1683545 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of activated charcoal administered 1.5 hours after 400 mg amiodarone
Number of subjects: 18
Study 1683545 — intervention group
Group type: COMPARATOR
Intervention: Control group with 400 mg amiodarone and water only
Number of subjects: 18
Study 7009592 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 0
Study 7009592 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 7009592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31331292 — intervention group
Group type: EXPERIMENTAL
Intervention: Massachusetts Child Psychiatry Access Program (MCPAP) for Moms
Number of subjects: 0
Study 31331292 — intervention group
Group type: EXPERIMENTAL
Intervention: PRogram In Support of Moms (PRISM) which includes MCPAP for Moms plus a proactive, multifaceted, practice-level intervention with intensive implementation support
Number of subjects: 0
Study 30646029 — intervention group
Group type: EXPERIMENTAL
Intervention: Greening intervention
Number of subjects: 442
Study 30646029 — intervention group
Group type: EXPERIMENTAL
Intervention: Greening intervention (for participants below the poverty line)
Number of subjects: 442
Study 30646029 — intervention group
Group type: EXPERIMENTAL
Intervention: Trash cleanup intervention
Number of subjects: 442
Study 30646029 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 442
Study 27427800 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training‐Oregon Model (PMTO®)
Number of subjects: 238
Study 27427800 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 238
Study 24760261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fat diet
Number of subjects: 227
Study 24760261 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate diet
Number of subjects: 227
Study 24760261 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 227
Study 24760261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (lower fat and lower carbohydrate)
Number of subjects: 227
Study 22371872 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (individual counseling from health educators to promote physical activity with a healthful diet)
Number of subjects: 490
Study 22371872 — intervention group
Group type: COMPARATOR
Intervention: Usual care (advice from physicians about lifestyle for obesity reduction)
Number of subjects: 490
Study 22371872 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (for men)
Number of subjects: 490
Study 22371872 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (for women)
Number of subjects: 490
Study 20382428 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nonsteroidal anti-inflammatory drug (ketorolac)
Number of subjects: 61
Study 20382428 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroid (fluorometholone)
Number of subjects: 61
Study 20382428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 61
Study 18351473 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 247
Study 18351473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 247
Study 16227648 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 54
Study 16227648 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 54
Study 14646439 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel (Instillagel) intraurethrally for approximately 15 min
Number of subjects: 140
Study 14646439 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble gel (Aquagel) smeared around the scope and external urethral meatus
Number of subjects: 140
Study 11279320 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg once daily
Number of subjects: 127
Study 11279320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 8878360 — intervention group
Group type: EXPERIMENTAL
Intervention: Training using the Mental Retardation/Developmental Disabilities Adaptation of the Nursing Child Assessment Feeding Scale
Number of subjects: 12
Study 8878360 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 1994667 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 24
Study 1994667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg twice daily)
Number of subjects: 24
Study 1994667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6388170 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftifine
Number of subjects: 60
Study 6388170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29194847 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifunctional suprapubic catheter (MSC)
Number of subjects: 91
Study 28114683 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 3 (L3) sleep study
Number of subjects: 406
Study 28114683 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 4 (L4) sleep study
Number of subjects: 406
Study 28114683 — intervention group
Group type: COMPARATOR
Intervention: Level 1 (L1) PSG
Number of subjects: 406
Study 28134604 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA and barrier membrane
Number of subjects: 18
Study 28134604 — intervention group
Group type: COMPARATOR
Intervention: Control (no buccal grafting)
Number of subjects: 18
Study 24998121 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchman Left Atrial Appendage Closure device
Number of subjects: 407
Study 24998121 — intervention group
Group type: COMPARATOR
Intervention: Chronic warfarin therapy
Number of subjects: 407
Study 22726232 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity (PA) for 12 months
Number of subjects: 424
Study 19233692 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) alone
Number of subjects: 265
Study 19233692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined deferiprone-deferoxamine (DFP-DFO)
Number of subjects: 265
Study 19233692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential deferiprone-deferoxamine (DFP-DFO)
Number of subjects: 265
Study 19233692 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (DFO)
Number of subjects: 265
Study 17595355 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg q.d. for 12 weeks followed by 45 mg q.d. for another 12 weeks)
Number of subjects: 735
Study 17595355 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg q.d. followed by 4 mg b.i.d. for the same intervals)
Number of subjects: 735
Study 15124248 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 411
Study 15124248 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid
Number of subjects: 411
Study 15124248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 10928202 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive approach to AIDS education focusing on internal dialogue and self-justifications during high-risk sex decision-making.
Number of subjects: 0
Study 10928202 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled intervention studies confronting gay men with their thinking during high-risk sex.
Number of subjects: 0
Study 8807687 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to Section 8 rent subsidy certificates
Number of subjects: 0
Study 8807687 — intervention group
Group type: COMPARATOR
Intervention: No access to Section 8 rent subsidy certificates
Number of subjects: 0
Study 8807687 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive case management services
Number of subjects: 0
Study 8807687 — intervention group
Group type: COMPARATOR
Intervention: Flexible case management services
Number of subjects: 0
Study 1423953 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units urokinase i.v. over 90 minutes plus intravenous heparin (group A)
Number of subjects: 149
Study 1423953 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units urokinase i.v. plus 325 mg aspirin p.o. daily (group B)
Number of subjects: 149
Study 1423953 — intervention group
Group type: COMPARATOR
Intervention: Placebo thrombolytic infusion plus full‐dose heparin (group C)
Number of subjects: 149
Study 4015359 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic tapping
Number of subjects: 20
Study 4015359 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic jabbing
Number of subjects: 20
Study 4015359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous stimulation of the thigh
Number of subjects: 20
Study 4015359 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 20
Study 31140907 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG + 5% NaOCl
Number of subjects: 95
Study 31140907 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG
Number of subjects: 95
Study 31140907 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG + Diode
Number of subjects: 95
Study 31140907 — intervention group
Group type: COMPARATOR
Intervention: 5% NaOCl
Number of subjects: 95
Study 29529449 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to MMT protocol
Number of subjects: 418
Study 29529449 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived institutional support
Number of subjects: 418
Study 29529449 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative attitudes towards PWUD
Number of subjects: 418
Study 29529449 — intervention group
Group type: EXPERIMENTAL
Intervention: National-level MMT training
Number of subjects: 418
Study 27136622 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly (ew)
Number of subjects: 154
Study 27136622 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week (eow)
Number of subjects: 154
Study 27136622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 22489516 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 65
Study 22489516 — intervention group
Group type: COMPARATOR
Intervention: Traction
Number of subjects: 65
Study 20819563 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg of body weight, daily) for continuous 7 days
Number of subjects: 33
Study 20819563 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 17178185 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin depot-3.75 i.m. (30 patients)
Number of subjects: 60
Study 17178185 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (30 patients)
Number of subjects: 60
Study 16151029 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver training
Number of subjects: 232
Study 12672860 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily for 28 weeks
Number of subjects: 252
Study 12672860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 11007727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 22
Study 11007727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8617705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 micrograms plus atenolol 50 mg
Number of subjects: 10
Study 8617705 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus atenolol 50 mg
Number of subjects: 10
Study 1616431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure breathing schedule with mean mask cavity pressures of 0 mm Hg
Number of subjects: 9
Study 1616431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure breathing schedule with mean mask cavity pressures of 18 mm Hg
Number of subjects: 9
Study 1616431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure breathing schedule with mean mask cavity pressures of 38 mm Hg
Number of subjects: 9
Study 1616431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure breathing schedule with mean mask cavity pressures of 60 mm Hg
Number of subjects: 9
Study 1616431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure breathing schedule with mean mask cavity pressures of 73 mm Hg
Number of subjects: 9
Study 3888388 — intervention group
Group type: EXPERIMENTAL
Intervention: vindesine plus cisplatin (vindesine 3 mg/m2, cisplatin 120 mg/m2)
Number of subjects: 108
Study 3888388 — intervention group
Group type: COMPARATOR
Intervention: vinblastine plus cisplatin (vinblastine 6 mg/m2, cisplatin 120 mg/m2)
Number of subjects: 108
Study 3888388 — intervention group
Group type: COMPARATOR
Intervention: vinblastine plus cisplatin
Number of subjects: 108
Study 30621836 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy with symptoms
Number of subjects: 1141
Study 30621836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonroutine reasons for contact
Number of subjects: 1141
Study 30249632 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of myo-inositol powder, twice daily until delivery
Number of subjects: 200
Study 30249632 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily until delivery
Number of subjects: 200
Study 26827980 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat varnish (Colgate‐Palmolive, New York, NY) applied to 6 teeth
Number of subjects: 24
Study 26827980 — intervention group
Group type: COMPARATOR
Intervention: Unvarnished control teeth (6 teeth)
Number of subjects: 24
Study 24660154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 96
Study 24660154 — intervention group
Group type: COMPARATOR
Intervention: Rectal acetaminophen
Number of subjects: 96
Study 22924336 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-Citrate-Simethicone (PEG-CS) with bisacodyl
Number of subjects: 408
Study 22924336 — intervention group
Group type: COMPARATOR
Intervention: PEG-Ascorbate (PEG-ASC)
Number of subjects: 408
Study 20229056 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan with other anti-hypertensives (n = 47)
Number of subjects: 97
Study 20229056 — intervention group
Group type: COMPARATOR
Intervention: Other anti-hypertensives alone (n = 50)
Number of subjects: 97
Study 18570547 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consult prior to face-to-face consultation
Number of subjects: 30
Study 18570547 — intervention group
Group type: COMPARATOR
Intervention: No telemedicine consult (control group)
Number of subjects: 30
Study 18082485 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 daily injection of insulin glargine (titrated to achieve fasting plasma glucose < or = 5.3 mmol/L)
Number of subjects: 12612
Study 18082485 — intervention group
Group type: EXPERIMENTAL
Intervention: omega‐3‐acid ethyl esters 90 (1 g consisting of EPA 465 mg and DHA 375 mg)
Number of subjects: 12612
Study 18082485 — intervention group
Group type: COMPARATOR
Intervention: standard glycemic care
Number of subjects: 12612
Study 18082485 — intervention group
Group type: COMPARATOR
Intervention: identical placebo
Number of subjects: 12612
Study 15678738 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy
Number of subjects: 33
Study 15678738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask (LM) airway
Number of subjects: 33
Study 15678738 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic laryngoscopy
Number of subjects: 33
Study 11726736 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg orally in two doses of 10 mg each, with a 1-h interval)
Number of subjects: 10
Study 11726736 — intervention group
Group type: COMPARATOR
Intervention: Septic controls (n=10, not treated with melatonin)
Number of subjects: 10
Study 11726736 — intervention group
Group type: COMPARATOR
Intervention: Healthy newborns (normal controls, n=10)
Number of subjects: 10
Study 9323286 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose and divided-dose prednisolone
Number of subjects: 106
Study 8517508 — intervention group
Group type: EXPERIMENTAL
Intervention: Background infusion (BI) at 1 mg/hr with patient-controlled analgesia (PCA)
Number of subjects: 62
Study 8517508 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) alone
Number of subjects: 62
Study 3705683 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (3 X 60 mg daily)
Number of subjects: 16
Study 3705683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11199945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus pindolol
Number of subjects: 111
Study 11199945 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine plus placebo
Number of subjects: 111
Study 29206754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonceliac wheat sensitivity (NCWS) patients
Number of subjects: 45
Study 29206754 — intervention group
Group type: COMPARATOR
Intervention: Celiac disease (CD) patients
Number of subjects: 45
Study 29206754 — intervention group
Group type: COMPARATOR
Intervention: Seronegative celiac disease patients
Number of subjects: 45
Study 29206754 — intervention group
Group type: COMPARATOR
Intervention: Irritable bowel syndrome (IBS) patients
Number of subjects: 45
Study 30049473 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet
Number of subjects: 634
Study 30049473 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 634
Study 26384556 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care intervention
Number of subjects: 2850
Study 26384556 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a living will and dying in the setting of full support
Number of subjects: 2850
Study 26384556 — intervention group
Group type: EXPERIMENTAL
Intervention: Family minority race
Number of subjects: 2850
Study 26384556 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and family education
Number of subjects: 2850
Study 24731672 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (2 mg subcutaneous injection once weekly)
Number of subjects: 456
Study 24731672 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (titrated to target once daily)
Number of subjects: 456
Study 24731672 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 456
Study 24731672 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 456
Study 22995705 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam HR single‐camera
Number of subjects: 0
Study 22995705 — intervention group
Group type: EXPERIMENTAL
Intervention: Galilei G2 dual‐camera
Number of subjects: 0
Study 22995705 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both devices
Number of subjects: 0
Study 19540783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT) at 4±0.2 degrees C
Number of subjects: 30
Study 19540783 — intervention group
Group type: COMPARATOR
Intervention: Hot Water Immersion Test (HIT) at 47±0.5 degrees C (cut-off point 5 min)
Number of subjects: 30
Study 18953212 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 18953212 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0
Study 16006907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (CBJ) 1 liter daily
Number of subjects: 24